Leukotuximab  (Synonyms: ART-140; DNP-001; EGX-040)

Leukotuximab (ART-140; EGX-040) is an anti-JL1 mAb and an anti-leukemic agent. Leukotuximab targets the JL1 epitope of CD43 and exerts cytotoxic effects on JL1-positive leukemia cells. Except for thymocytes and some bone marrow mononuclear cells, Leukotuximab causes no damage to most normal tissues. Leukotuximab can be used in the research of acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome^[1][2].

Human

The JL1 antigen is expressed on leukemia cells in more than half of AML patients. The anti-JL1 antibody Leukotuximab has been used in a Phase I study for acute leukemia cases in Korea^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

6693  [NCBI]

P16150

CD43/Leukosialin

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

[Leukotuximab]

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Rashidi A, et al. Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?[J]. Expert review of hematology, 2016, 9(4): 335-350.

  [2]. Park H S, et al. Expression of JL1 antigen in acute leukemia and myelodysplastic syndrome[J]. Blood, 2015, 126(23): 3826.